Biocryst Pharmaceuticals Inc
Biocryst Pharmaceuticals Inc logo
BCRX

Biocryst Pharmaceuticals Inc (BCRX)

$10.510.38%

Live
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$10.29
Day's Range
$10.56
$7.61
52-Week Range
$19.99
1 month return10.74%
3 month return10.82%
1 year return35.59%
5 year return120.71%

Analyst Recommendation

based on 18 analysts ratings

Buy
61%
Buy
38%
Hold
0%
Sell

Based on 18 Wall street analysts offering stock ratings for Biocryst Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 58.9%

Current

$10.51

Target

$16.7

Recommendation Trend

Based on 18 analyst

Current1M Ago3M Ago
Buy
11
10
11
Hold
7
3
7
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization2.0B
Book Value- $1.3
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-1.07
PEG Ratio-0.28
Wall Street Target Price16.7

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)56.59
Enterprise Value2.3B
Enterprise Value/Revenue9.45
Enterprise Value/Ebitda-23.51

Technicals

Beta2.03
50 Day MA11.15
200 Day MA11.66

Institutional Holdings

Vanguard Group Inc

7.42%

BlackRock Inc

7.39%

Baker Bros Advisors LP

6.82%

State Street Corporation

5.04%

venBio Select Advisor LLC

4.85%

FMR Inc

3.06%

Company Information

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.
OrganizationBiocryst Pharmaceuticals Inc
Employees358
CEOMr. Jon P. Stonehouse
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Biocryst Pharmaceuticals Inc share price today?

Can Indians buy Biocryst Pharmaceuticals Inc shares?

How can I buy Biocryst Pharmaceuticals Inc shares from India?

Can Fractional shares of Biocryst Pharmaceuticals Inc be purchased?

What are the documents required to start investing in Biocryst Pharmaceuticals Inc stocks?

What are today’s High and Low prices of Biocryst Pharmaceuticals Inc?

What are today’s traded volumes of Biocryst Pharmaceuticals Inc?

What is today’s market capitalisation of Biocryst Pharmaceuticals Inc?

What is the 52 Week High and Low Range of Biocryst Pharmaceuticals Inc?

How much percentage Biocryst Pharmaceuticals Inc is down from its 52 Week High?

How much percentage Biocryst Pharmaceuticals Inc is up from its 52 Week low?

What are the historical returns of Biocryst Pharmaceuticals Inc?

Who is the Chief Executive Officer (CEO) of Biocryst Pharmaceuticals Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*